Age-Related Macular Degeneration Pipeline Highlights – 2017

Age-Related Macular Degeneration Pipeline Highlights – 2017

  • January 2017 •
  • Report ID: 3894656 •
  • Format: PDF
The latest report from Fore Pharma, Age-Related Macular Degeneration Pipeline Highlights – 2017, provides most up-to-date information on key pipeline products in the global Age-Related Macular Degeneration market.

It covers emerging therapies for Age-Related Macular Degeneration in active clinical development stages including early and late stage clinical trials. The pipeline data presented in this report helps executives for tracking competition, identifying partners, evaluating opportunities, formulating business development strategies, and executing in-licensing and out-licensing deals.

Clinical Trial Stages:
The report provides Age-Related Macular Degeneration pipeline products by clinical trial stages including both early and late stage development - phase 3 clinical trials, phase 2 clinical trials, phase 1 clinical trials, preclinical research, and discovery stage.

Drug Mechanism Classes:
The report provides Age-Related Macular Degeneration pipeline products by their dominant mechanism of action. This helps executives categorize products based on their drug class and also assess the strengths and weaknesses of compounds.

Company:
The report provides Age-Related Macular Degeneration pipeline products by the company.

Short-term Launch Highlights:
Find out which Age-Related Macular Degeneration pipeline products will be launched in the US and Ex-US till 2020.

SUMMARY:
- Age-Related Macular Degeneration phase 3 clinical trial pipeline products
- Age-Related Macular Degeneration phase 2 clinical trial pipeline products
- Age-Related Macular Degeneration phase 1 clinical trial pipeline products
- Age-Related Macular Degeneration preclinical research pipeline products
- Age-Related Macular Degeneration discovery stage pipeline products
- Age-Related Macular Degeneration pipeline products short-term launch highlights